83782-30-3

Basic information

• Product Name: 2-(((2-bromophenyl)thio)methyl)pyridine
• CAS NO: 83782-30-3
• Molecular Weight: 280.188
• Mol File: 83782-30-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(((2-bromophenyl)thio)methyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(((2-bromophenyl)thio)methyl)pyridine(83782-30-3)
• EPA Substance Registry System: 2-(((2-bromophenyl)thio)methyl)pyridine(83782-30-3)

Safety Data

• Hazardous Substances Data: 83782-30-3(Hazardous Substances Data)

Upstream product

• 586-98-1 2-Hydroxymethylpyridine 
• 6320-02-1 o-bromothiophenol 
• 10299-21-5 2-trifluoroacetoxymethylpyridine 

Relevant articles and documents

Synthesizing method of 2-pyridine methyl sulfide and synthesizing process of related drugs

The invention relates to a simple synthesizing method of 2-pyridine methyl sulfide and related drugs. The method is characterized in that 2-methyl pyridine n-oxide is used as the raw material and pyridine n-oxide or dichloromethane is used as the solvent to have reaction with trifluoroacetic anhydride to obtain a trifluoroacetate intermediate, purification is not needed, the trifluoroacetate intermediate is allowed to have reaction with thiophenol under the catalysis of lithium bromide or tetrabutyl ammonium bromide and by using toluene or ethyl acetate as the solvent to generate the 2-pyridine methyl sulfide. The method is simple to operate, cheap in reagents, easy in reagent obtaining, mild in reaction conditions, wide in substrate applicability, good in position selectivity, high in yield and the like. In addition, the method is successfully applied to the synthesizing of omeprazole sulfide and rabeprazole sulfide, and the synthesizing method does not need catalysts.

2-pyridine Derivatives: New Antiinflammatory Agents

2-pyridine derivatives (1a-e) inhibited the dermal reverse passive Arthus reaction (RPAR) in the rat.In the same model, indomethacin was inactive, and hydrocortisone was active.Compounds 1a-d also significantly reduced exudate volume and white blood cell accumulation in the pleural RPAR.This pattern of activity was similar to that of hydrocortisone and different from that of indomethacin.